KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.Oral OncolPMID 34560383无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial.Eur J CancerPMID 34563992无 PMCID2021-Nov1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ.Radiother OncolPMID 34571090无 PMCID2021-Nov0.90While this is a report from a definitive phase III randomized oncology trial in humans, it does not include the required survival, progression, recurrence, death, or time-to-event efficacy outcomes. It reports on quality assurance and acute toxicities only.待处理
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.Eur J CancerPMID 34571336PMC93508852021-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Weight loss and its impact on outcome in head and cancer patients during chemo-radiation.Oral OncolPMID 34571463无 PMCID2021-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.Eur J CancerPMID 34597975无 PMCID2021-Nov0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.Lancet OncolPMID 34600602PMC93774122021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial.Radiother OncolPMID 34619239无 PMCID2021-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.Lancet HIVPMID 34648734无 PMCID2021-Nov0.98未发现恶性肿瘤人群证据。待处理
Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.Cancer MedPMID 34655175PMC85594922021-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.Lancet OncolPMID 34655533无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.Lancet OncolPMID 34656227PMC85606422021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.BioDrugsPMID 34657274PMC85204672021-Nov0.98未发现恶性肿瘤人群证据。待处理
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.Lancet Glob HealthPMID 34678198PMC85516812021-Nov0.98未发现恶性肿瘤人群证据。待处理
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study.Target OncolPMID 34687398PMC86131172021-Nov0.85This is a report of a Phase Ib study component of a larger trial, not a definitive Phase III/IIIb or Phase II/III report. The primary endpoints were safety (dose-limiting toxicities) and objective response (ORR/CR/PR), not a time-to-event efficacy endpoint like OS or PFS. The study was discontinued before the Phase III component was initiated.待处理
Measuring treatment response to advance precision medicine for multiple sclerosis.Ann Clin Transl NeurolPMID 34704393PMC86074512021-Nov0.98未发现恶性肿瘤人群证据。待处理
Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses.Mol Genet MetabPMID 34716085无 PMCID2021-Nov0.98未发现恶性肿瘤人群证据。待处理
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).DrugsPMID 34724172PMC86021542021-Nov0.98未发现恶性肿瘤人群证据。待处理
Intra-Articular Injection of a Novel DVS Cross-Linked Hyaluronic Acid Manufactured by Biological Fermentation (YYD302) in Patients With Knee Osteoarthritis: A Double-Blind, Randomized, Multicenter, Noninferiority Study.Clin TherPMID 34736768无 PMCID2021-Nov0.98未发现恶性肿瘤人群证据。待处理
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.Nat MedPMID 34737452无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Timing and durability of response to erenumab in patients with episodic migraine.HeadachePMID 34841526无 PMCID2021-Nov0.98未发现恶性肿瘤人群证据。待处理
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.JCO Precis OncolPMID 34994614无 PMCID2021-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.J Hematol OncolPMID 34717692PMC85569752021-Oct-300.95The study is an eligible oncology Phase III randomized trial with a drug intervention, but the reported efficacy endpoints are safety (DLTs, TLS) and response rates (ORR, CR), not time-to-event survival endpoints (e.g., OS, PFS) required for inclusion in the KM digitization cohort.待处理
A Protective Role for Arachidonic Acid Metabolites against Advanced Colorectal Adenoma in a Phase III Trial of Selenium.NutrientsPMID 34836131PMC86210082021-Oct-290.85This is a Phase III randomized trial of selenium (a dietary supplement) for colorectal adenoma prevention. However, the abstract describes a biomarker analysis (oxylipins) within the trial, not a primary time-to-event efficacy endpoint. The outcomes are odds ratios for adenoma characteristics at baseline and associations with new adenoma development during follow-up, but no time-to-event analysis (KM, HR, OS/PFS/DFS/etc.) is mentioned. The intervention (selenium) is a dietary supplement, not a conventional drug. Therefore, it does not meet the required criteria for a time-to-event efficacy endpoint or a drug-containing intervention.待处理
Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).Kidney360PMID 35372979PMC87857782021-Oct-280.98未发现恶性肿瘤人群证据。待处理
A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.VaccinePMID 34620531PMC84612222021-Oct-220.98未发现恶性肿瘤人群证据。待处理
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.BloodPMID 34157093PMC97104692021-Oct-210.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.J Clin Endocrinol MetabPMID 34272849PMC85307272021-Oct-210.98未发现恶性肿瘤人群证据。待处理
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.N Engl J MedPMID 34525276PMC84615672021-Oct-210.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.NeurologyPMID 34433679PMC92460832021-Oct-190.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of a single intra-articular injection of a novel enhanced protein solution (JTA-004) compared to hylan G-F 20 in symptomatic knee osteoarthritis: a randomized, double-blind, controlled phase II/III study.BMC Musculoskelet DisordPMID 34666767PMC85278072021-Oct-190.98未发现恶性肿瘤人群证据。待处理
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial.Clin Cancer ResPMID 34083233无 PMCID2021-Oct-150.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.Clin Cancer ResPMID 34326132PMC94014932021-Oct-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).VaccinePMID 34489128无 PMCID2021-Oct-150.98未发现恶性肿瘤人群证据。待处理
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.Signal Transduct Target TherPMID 34650034PMC85170122021-Oct-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).BMC CancerPMID 34654402PMC85182652021-Oct-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.N Engl J MedPMID 34644472无 PMCID2021-Oct-140.98未发现恶性肿瘤人群证据。待处理
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.J Am Coll CardiolPMID 34620410无 PMCID2021-Oct-120.98未发现恶性肿瘤人群证据。待处理
Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).J Clin OncolPMID 34156881无 PMCID2021-Oct-100.85The report is a secondary analysis from a definitive randomized Phase III oncology trial, but its outcomes (gonadal function, fertility) are not survival, progression, recurrence, death, or other time-to-event efficacy measures required for inclusion in this cohort.待处理
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.J Clin OncolPMID 34379443PMC85006032021-Oct-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study.BMC PsychiatryPMID 34625041PMC85017012021-Oct-080.98未发现恶性肿瘤人群证据。待处理
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.N Engl J MedPMID 34260849PMC83147852021-Oct-070.98未发现恶性肿瘤人群证据。待处理
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.Nat CommunPMID 34615860PMC84949132021-Oct-060.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of a Naphthoquine-Azithromycin Coformulation for Malaria Prophylaxis in Southeast Asia: A Phase 3, Double-blind, Randomized, Placebo-controlled Trial.Clin Infect DisPMID 32687174PMC84921152021-Oct-050.98未发现恶性肿瘤人群证据。待处理
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).Clin Infect DisPMID 32897367PMC84922202021-Oct-050.98未发现恶性肿瘤人群证据。待处理
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.J Am Coll CardiolPMID 34593120无 PMCID2021-Oct-050.98未发现恶性肿瘤人群证据。待处理
Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries.Hum Vaccin ImmunotherPMID 34181506PMC84374812021-Oct-030.98未发现恶性肿瘤人群证据。待处理
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.Crit CarePMID 34600585PMC84873372021-Oct-020.98未发现恶性肿瘤人群证据。待处理
Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial.J Natl Cancer InstPMID 33822134PMC84863252021-Oct-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.J Clin OncolPMID 34048275PMC84783922021-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理